{"nctId":"NCT00884221","briefTitle":"MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer","startDateStruct":{"date":"2009-07"},"conditions":["Infertility"],"count":749,"armGroups":[{"label":"Highly Purified Menotrophin","type":"EXPERIMENTAL","interventionNames":["Drug: Highly purified menotrophin"]},{"label":"Recombinant FSH","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Recombinant FSH"]}],"interventions":[{"name":"Highly purified menotrophin","otherNames":["HP-hMG","MENOPUR"]},{"name":"Recombinant FSH","otherNames":["Follitrophin-beta","PUREGON","FOLLISTIM"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Informed Consent Documents signed prior to screening evaluations\n* In good physical and mental health\n* Pre-menopausal females 21-34 years of age\n* Body mass index (BMI)18-25 kg/m2\n* Eligible for intracytoplasmic sperm injection (ICSI)\n* Unexplained infertility or partner with mild male factor infertility\n* Infertility for at least 12 months before randomization\n* Regular menstrual cycles of 24-35 days, presumed to be ovulatory\n* Hysterosalpingography, hysteroscopy, or transvaginal ultrasound documenting a uterus consistent with expected normal function\n* Transvaginal ultrasound documenting expected normal function of the ovaries\n* Early follicular phase serum levels of FSH between 1 and 12 IU/L\n* Early follicular phase total antral follicle (diameter 2-10 mm) count ≥ 10 for both ovaries combined\n* Willing to accept transfer of one blastocyst in the fresh cycle\n* Willing to undergo frozen embryo replacement cycles with transfer of one blastocyst per cycle within the first year after randomisation\n\nExclusion criteria:\n\n* Known polycystic ovarian syndrome or known endometriosis stage I-IV\n* Diagnosed as \"poor responder\" in a previous controlled ovarian stimulation (COS) cycle\n* Severe ovarian hyperstimulation syndrome (OHSS)in a previous COS cycle\n* History of recurrent miscarriage\n* Current or past (12 months prior to randomization) abuse of alcohol or drugs, and/or current (last month) intake of more than 14 units of alcohol per week\n* Current or past smoking habit of more than 10 cigarettes per day\n* Hypersensitivity to any active ingredient or excipients in the medicinal products used in the trial\n* Hypersensitivity to gonadotrophin-releasing hormone (GnRH) or any other GnRH analogue\n* Previous participation in the trial\n* Use of any non registered investigational drugs during 3 months before randomization","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"21 Years","maximumAge":"34 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Ongoing Pregnancy After One Fresh Embryo Replacement Cycle, Intention-to-treat (ITT) Analysis Set","description":"Transvaginal ultrasound showing at least one intrauterine viable fetus 10-11 weeks after embryo transfer at the blastocyst stage","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":"2.3"},{"groupId":"OG001","value":"27","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"Endocrine Profile (Estradiol), Intention-to-treat (ITT) Analysis Set","description":"Blood samples for analysis of circulating concentrations of endocrine parameters were drawn","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8797","spread":"6030"},{"groupId":"OG001","value":"7022","spread":"4945"}]}]}]},{"type":"SECONDARY","title":"Endocrine Profile (FSH), Intention-to-treat (ITT) Analysis Set","description":"Blood samples for analysis of circulating concentrations of endocrine parameters were drawn","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.7","spread":"4.1"},{"groupId":"OG001","value":"12.6","spread":"3.7"}]}]}]},{"type":"SECONDARY","title":"Endocrine Profile (Free Androgen Index), Intention-to-treat (ITT) Analysis Set","description":"Blood samples for analysis of circulating concentrations of endocrine parameters were drawn. Free androgen index = (testosterone (nmol/L)/ sex hormone binding globulin (nmol/L))\\*100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"2.0"},{"groupId":"OG001","value":"2.5","spread":"2.2"}]}]}]},{"type":"SECONDARY","title":"Endocrine Profile (Luteinizing Hormone), Intention-to-treat (ITT) Analysis Set","description":"Blood samples for analysis of circulating concentrations of endocrine parameters were drawn","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"2.8"},{"groupId":"OG001","value":"2.1","spread":"1.6"}]}]}]},{"type":"SECONDARY","title":"Endocrine Profile (Progesterone), Intention-to-treat (ITT) Analysis Set","description":"Blood samples for analysis of circulating concentrations of endocrine parameters were drawn","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"3.4"},{"groupId":"OG001","value":"3.1","spread":"3.3"}]}]}]},{"type":"PRIMARY","title":"Ongoing Pregnancy After One Fresh Embryo Replacement Cycle, Per-protocol (PP) Analysis Set","description":"Transvaginal ultrasound showing at least one intrauterine viable fetus 10-11 weeks after embryo transfer at the blastocyst stage","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":"2.5"},{"groupId":"OG001","value":"27","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Endocrine Profile (Prolactin), Intention-to-treat (ITT) Analysis Set","description":"Blood samples for analysis of circulating concentrations of endocrine parameters were drawn","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1544","spread":"770"},{"groupId":"OG001","value":"1410","spread":"689"}]}]}]},{"type":"SECONDARY","title":"Endocrine Profile (Sex Hormone Binding Globulin), Intention-to-treat (ITT) Analysis Set","description":"Blood samples for analysis of circulating concentrations of endocrine parameters were drawn","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":"51"},{"groupId":"OG001","value":"107","spread":"48"}]}]}]},{"type":"SECONDARY","title":"Endocrine Profile (Testosterone), Intention-to-treat (ITT) Analysis Set","description":"Blood samples for analysis of circulating concentrations of endocrine parameters were drawn","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":"1.2"},{"groupId":"OG001","value":"2.1","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Number of Follicles of >= 12mm, 12-14 mm, 15-16 mm and >= 17 mm in Each Participant, Intention-to-treat (ITT) Analysis Set","description":"During the controlled ovarian stimulation, transvaginal ultrasound was performed to count the number of follicles and measure the size of the follicles.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":"4.7"},{"groupId":"OG001","value":"11.8","spread":"4.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"2.6"},{"groupId":"OG001","value":"3.8","spread":"2.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"2.2"},{"groupId":"OG001","value":"2.7","spread":"2.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":"2.2"},{"groupId":"OG001","value":"5.2","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Number of Oocytes Retrieved in Each Participant, Intention-to-treat (ITT) Analysis Set","description":"Oocyte retrieval took place 36h (± 2h) after hCG administration. At oocyte retrieval, the number of oocytes retrieved was recorded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1","spread":"5.2"},{"groupId":"OG001","value":"10.7","spread":"5.8"}]}]}]},{"type":"SECONDARY","title":"Fertilization, Intention-to-treat (ITT) Analysis Set","description":"Fertilized oocytes with 2 pronuclei were regarded as correctly fertilized. Fertilization was estimated as (Number of oocytes with 2 pronuclei / number of metaphase II oocytes)\\*100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":"23"},{"groupId":"OG001","value":"76","spread":"22"}]}]}]},{"type":"SECONDARY","title":"Blastocyst Quality, Intention-to-treat (ITT) Analysis Set","description":"Blastocyst quality on day 5 was based on the blastocyst expansion and hatching status, inner cell mass grading and trophectoderm grading.\n\nExcellent-quality blastocysts were defined as those with blastocyst expansion and hatching status 4, 5 or 6, inner cell mass grading A, and trophectoderm grading A or B. Good-quality blastocysts were defined as those with blastocyst expansion and hatching status 3, 4, 5 or 6, inner cell mass grading A or B, and trophectoderm grading A or B.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":"17"},{"groupId":"OG001","value":"7","spread":"16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":"15"},{"groupId":"OG001","value":"5","spread":"11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":"16"},{"groupId":"OG001","value":"10","spread":"15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":"22"},{"groupId":"OG001","value":"20","spread":"26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":"16"},{"groupId":"OG001","value":"6","spread":"13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"13"},{"groupId":"OG001","value":"5","spread":"14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":"7"},{"groupId":"OG001","value":"2","spread":"7"}]}]}]},{"type":"SECONDARY","title":"Live Birth for a Single Stimulation Cycle With Single Blastocyst Transfer From Fresh Embryo Replacement Cycle, Intention-to-treat (ITT) Analysis Set","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":"2.3"},{"groupId":"OG001","value":"26","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"Cumulative Live Birth for a Single Stimulation Cycle With Single Blastocyst Transfer From Fresh and 1 Year Frozen Embryo Replacement Cycles, Intention-to-treat (ITT) Analysis Set","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":"2.5"},{"groupId":"OG001","value":"38","spread":"2.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":374},"commonTop":["Abortion spontaneous","Headache","Pelvic pain","Nausea","Vaginal haemorrhage"]}}}